BACKGROUND AND PURPOSE: QT prolongation is commonly used as a surrogate marker for Torsade de Pointes (TdP) risk of non-cardiovascular drugs. However, use of this indirect marker often leads to misinterpretation of the realistic TdP risk, as tested compounds may cause QT prolongation without evoking TdP in humans. A negative electro-mechanical (E-M) window has recently been proposed as an alternative risk marker for TdP in a canine LQT1 model. Here, we evaluated the E-M window in anaesthetized guinea pigs as a screening marker for TdP in humans. EXPERIMENTAL APPROACH: The effects of various reference drugs and changes in body temperature on the E-M window were assessed in instrumented guinea pigs. The E-M window was defined as the delay between the duration of the electrical (QT interval) and mechanical (QLVP(end) ) systole. KEY RESULTS: Drugs with known TdP liability (quinidine, haloperidol, domperidone, terfenadine, thioridazine and dofetilide), but not those with no TdP risk in humans (salbutamol and diltiazem) consistently decreased the E-M window. Interestingly, drugs with known clinical QT prolongation, but with low risk for TdP (amiodarone, moxifloxacin and ciprofloxacin) did not decrease the E-M window. Furthermore, the E-M window was minimally affected by changes in heart rate or body temperature. CONCLUSIONS AND IMPLICATIONS: A decreased E-M window was consistently observed with drugs already known to have high TdP risk, but not with drugs with low or no TdP risk. These results suggest that the E-M window in anaesthetized guinea pigs is a risk marker for TdP in humans.
BACKGROUND AND PURPOSE: QT prolongation is commonly used as a surrogate marker for Torsade de Pointes (TdP) risk of non-cardiovascular drugs. However, use of this indirect marker often leads to misinterpretation of the realistic TdP risk, as tested compounds may cause QT prolongation without evoking TdP in humans. A negative electro-mechanical (E-M) window has recently been proposed as an alternative risk marker for TdP in a canine LQT1 model. Here, we evaluated the E-M window in anaesthetized guinea pigs as a screening marker for TdP in humans. EXPERIMENTAL APPROACH: The effects of various reference drugs and changes in body temperature on the E-M window were assessed in instrumented guinea pigs. The E-M window was defined as the delay between the duration of the electrical (QT interval) and mechanical (QLVP(end) ) systole. KEY RESULTS: Drugs with known TdP liability (quinidine, haloperidol, domperidone, terfenadine, thioridazine and dofetilide), but not those with no TdP risk in humans (salbutamol and diltiazem) consistently decreased the E-M window. Interestingly, drugs with known clinical QT prolongation, but with low risk for TdP (amiodarone, moxifloxacin and ciprofloxacin) did not decrease the E-M window. Furthermore, the E-M window was minimally affected by changes in heart rate or body temperature. CONCLUSIONS AND IMPLICATIONS: A decreased E-M window was consistently observed with drugs already known to have high TdP risk, but not with drugs with low or no TdP risk. These results suggest that the E-M window in anaesthetized guinea pigs is a risk marker for TdP in humans.
Authors: Anthony R Magnano; Steve Holleran; Rajasekhar Ramakrishnan; James A Reiffel; Daniel M Bloomfield Journal: J Am Coll Cardiol Date: 2002-06-05 Impact factor: 24.094
Authors: J M van Opstal; M Schoenmakers; S C Verduyn; S H de Groot; J D Leunissen; F F van Der Hulst; M M Molenschot; H J Wellens; M A Vos Journal: Circulation Date: 2001-11-27 Impact factor: 29.690
Authors: W S Redfern; L Carlsson; A S Davis; W G Lynch; I MacKenzie; S Palethorpe; P K S Siegl; I Strang; A T Sullivan; R Wallis; A J Camm; T G Hammond Journal: Cardiovasc Res Date: 2003-04-01 Impact factor: 10.787
Authors: Stephen Zicha; Isaac Moss; Bruce Allen; Andras Varro; Julius Papp; Robert Dumaine; Charles Antzelevich; Stanley Nattel Journal: Am J Physiol Heart Circ Physiol Date: 2003-06-19 Impact factor: 4.733
Authors: T R G Stams; V J A Bourgonje; H D M Beekman; M Schoenmakers; R van der Nagel; P Oosterhoff; J M van Opstal; M A Vos Journal: Br J Pharmacol Date: 2014-02 Impact factor: 8.739
Authors: Pierre Morissette; Sebastian Polak; Anne Chain; Jin Zhai; John P Imredy; Mary Jo Wildey; Jeffrey Travis; Kevin Fitzgerald; Patrick Fanelli; Elisa Passini; Blanca Rodriguez; Frederick Sannajust; Christopher Regan Journal: Toxicol Appl Pharmacol Date: 2020-01-23 Impact factor: 4.219
Authors: Kristin Wisløff-Aase; Helge Skulstad; Kristina Haugaa; Per Snorre Lingaas; Jan Otto Beitnes; Per Steinar Halvorsen; Andreas Espinoza Journal: Physiol Rep Date: 2022-04
Authors: Katja E Odening; Henk J van der Linde; Michael J Ackerman; Paul G A Volders; Rachel M A Ter Bekke Journal: Eur Heart J Date: 2022-08-21 Impact factor: 35.855